Browse studies
Find your next paid study
28 recruiting studies matching your filters
Phase 1
Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus \[CMV\] specific cytotoxic …
Allogeneic Hematopoietic Stem Cell Transplantation RecipientCytomegalovirusDonor+2 more
Estimated
~$10 – $7,500
Sumithira VasuNCT03665675
Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study
The goal of this observational study is to collect information on the long-term safety of study participants who received an Allogeneic Chimeric Antigen Recept…
Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
Estimated
~$10 – $1,050
Imugene LimitedNCT05822427
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Low-Dose Post-Transplant Cyclophosphamide for Prophylaxis of Graft-versus-Host Disease in Hematological Malignancies
This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophyla…
Graft-versus-Host Disease (GVHD)Hematologic MalignanciesAllogeneic Stem Cell Transplantation
Estimated
~$10 – $6,250
Milton S. Hershey Medical CenterNCT06926595
Phase 1
An Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics in Patients With AML or MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
This study aim is to assess, if treosulfan pharmacokinetics are influenced by declined renal function and by race/ethnicity of patients. The study also aims to…
Acute Myeloid Leukaemia (AML)Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Estimated
~$10 – $8,750
medac GmbHNCT05534620